Insiders who reported open-market trades in the last 12 months at the companies Ian T. Clark files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Amirali Talasaz - $73.75M in GH purchases and sales in the last 12 months
Terilyn J. Monroe - $14.82M in GH purchases and sales in the last 12 months
Chris Freeman - $13.68M in GH purchases and sales in the last 12 months
Helmy Eltoukhy - $12.63M in GH purchases and sales in the last 12 months
Kumud Kalia - $5.78M in GH purchases and sales in the last 12 months
John G. Saia - $4.25M in GH purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Ian T. Clark is a corporate insider, tracked as Director of Guardant Health, Inc. (GH). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Ian T. Clark submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Ian T. Clark been buying or selling stock?
Recorded transactions: 0 open-market purchases and 5 open-market sales ($3.23M) across all tracked filings.
Ian T. Clark is Director of Guardant Health, Inc. (GH). 10 SEC Form 4 filings on record going back to 2024, most recently on 5 August 2026. Most recent open-market trade: sold $809K of GH on 5 August 2026. Lifetime open-market sales: $3.23M.
Recent transactions
15
The latest 15 SEC Form 4 transactions reported by Ian T. Clark.
InsiderAlpha's records for Ian T. Clark go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
